文献速递前列腺癌

多参数MRI在真实世界中预测前列腺癌病理与肿瘤分期的准确性评估:一项多中心研究

Evaluation of the accuracy of multiparametric MRI for predicting prostate cancer pathology and tumour staging in the real world: an multicentre study.
PubMed 文献 · BJU Int · 2019-02-25

该澳大利亚三中心研究纳入2013年1月至2016年8月根治性前列腺切除术(RP)前12个月内行多参数MRI(mpMRI)的235例男性,比较mpMRI与RP标本对显著前列腺癌检出、索引病灶定位及T3期预测的准确性。mpMRI PI-RADS评分≥3对RP显著前列腺癌的灵敏度为91%、阳性预测值为95%,索引病灶总体一致率为75%;PI-RADS第2版较第1版在显著前列腺癌预测灵敏度和索引病灶一致率上均有提高。

要点

  • mpMRI PI-RADS评分≥3对RP显著前列腺癌的灵敏度为91%、阳性预测值为95%。
  • mpMRI与RP标本的索引病灶总体一致率为75%,PI-RADS第2版组高于第1版组(91% vs 68%,P=0.002)。
  • mpMRI预测前列腺外疾病的灵敏度为38%、特异度为95%、阳性预测值为90%、阴性预测值为57%。

核心结论

  • 在接受RP的患者中,异常mpMRI对显著前列腺癌具有高度预测价值(阳性预测值95%),索引病灶一致率为75%。
  • 采用PI-RADS第2版技术规范与报告标准后准确性显著改善;但原文指出需进一步研究以确定该改善是源于mpMRI经验提升还是PI-RADS系统的变化。

研究设计与样本

  • 多中心研究,纳入2013年1月至2016年8月在澳大利亚三个中心(新南威尔士州Central Coast、维多利亚州墨尔本St Vincents Hospital、维多利亚州Bendigo Hospital)于RP前12个月内行mpMRI的男性,共235例。
  • 将mpMRI结果与最终RP标本比较,分析mpMRI对显著前列腺癌检出、索引病灶定位、T3期疾病预测及淋巴结转移预测的表现。
  • 并对采用PI-RADS第1版与第2版技术及报告规范的mpMRI病例进行比较;数据分析使用spss 24.0。

主要发现

  • mpMRI PI-RADS评分≥3对RP显著前列腺癌的灵敏度为91%、阳性预测值为95%。
  • mpMRI与RP标本的索引病灶位置总体一致率为75%。
  • 显著前列腺癌预测灵敏度在PI-RADS第2版病例中高于第1版(87-99%;P=0.005)。
  • 索引病灶一致率在PI-RADS第2版组更高(68% vs 91%;P=0.002)。
  • mpMRI预测前列腺外疾病的灵敏度为38%、特异度为95%、阳性预测值为90%、阴性预测值为57%;预测T3期疾病的灵敏度随PI-RADS第2版从30%提高至62%(P=0.008)。

关键数值与推荐

  • mpMRI PI-RADS评分≥3对RP显著前列腺癌的灵敏度为91%、阳性预测值为95%。
  • mpMRI与RP标本的索引病灶总体一致率为75%。
  • 显著前列腺癌预测灵敏度在PI-RADS第2版病例中高于第1版(87-99%;P=0.005)。
  • 索引病灶一致率在PI-RADS第2版组更高(68% vs 91%;P=0.002)。
  • mpMRI预测前列腺外疾病的灵敏度为38%、特异度为95%、阳性预测值为90%、阴性预测值为57%;预测T3期疾病的灵敏度随PI-RADS第2版从30%提高至62%(P=0.008)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需进一步研究以确定准确性改善是源于mpMRI经验提升还是PI-RADS系统的变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the accuracy of multiparametric magnetic resonance imaging (mpMRI) for the detection of significant prostate cancer in men undergoing radical prostatectomy (RP) in an Australian multicentre setting, and to assess concordance between mpMRI and RP for local tumour staging and index lesion locations. PATIENTS AND METHODS: Men who underwent mpMRI within 12 months of RP between January 2013 and August 2016 at three Australian sites were included (Central Coast, NSW, St Vincents Hospital, Melbourne, Vic., and Bendigo Hospital, Vic.). The results of mpMRI were compared with the final RP specimen to analyse the performance of mpMRI for significant prostate cancer detection, index lesion localization, prediction of T3 disease and lymph node metastasis. A comparison between mpMRI cases performed using the technical and reporting specifications of Prostate Imaging Reporting and Data System (PI-RADS) version 1 and version 2 was also performed. Data analysis was performed using spss 24.0. RESULTS: A total of 235 cases were included for analysis. mpMRI PI-RADS score ≥3 had a 91% sensitivity and 95% positive predictive value (PPV) for significant prostate cancer at RP. The overall concordance between index lesion location on mpMRI and RP specimen was 75%. The sensitivity for predication of significant prostate cancer was higher in the PI-RADS version 2 cases compared with PI-RADS version 1 (87-99%; P = 0.005). Index lesion concordance was higher in the PI-RADS version 2 group (68% vs 91%; P = 0.002). mpMRI had a 38% sensitivity, 95% specificity, 90% PPV and 57% negative predictive value for extraprostatic disease. Sensitivity for prediction of T3 disease improved from 30% to 62% (P = 0.008) with PI-RADS version 2. CONCLUSIONS: In patients undergoing RP, an abnormal mpMRI is highly predictive (95% PPV) of significant prostate cancer, with an index lesion concordance of 75%. There has been a significant improvement in accuracy after the adoption of PI-RADS version 2 technical specifications and reporting criteria; however; further study is required to determine if this is attributable to improved experience with mpMRI or changes in the PI-RADS system.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Kam J, Yuminaga Y, Krelle M, et al. Evaluation of the accuracy of multiparametric MRI for predicting prostate cancer pathology and tumour staging in the real world: an multicentre study. BJU Int. 2019. PMID: 30714285. doi:10.1111/bju.14696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。